Open public hearings
This article was originally published in The Tan Sheet
Executive Summary
Individuals who wish to present during open public hearings at advisory committee meetings are not required to disclose financial ties, FDA says in a draft guidance published in the Federal Register Feb. 15. Although disclosure is encouraged, panelists should not ask further questions about a potential link, but may ask for further details on scientific content, the draft guidance adds...You may also be interested in...
Open Public Hearing Speakers Should Disclose Financial Conflict – Comments
FDA should permit advisory committee members and voting consultants to question open public hearing speakers about their potential conflicts of interest during advisory committee meetings, according to the consumer advocacy group Public Citizen
Pfizer Upjohn’s Ray On Changing The Grave Trajectory Of NCDs
Pfizer Upjohn’s Global President of R&D and Medical, Amrit Ray, talks in a wide-ranging interview about the need for tailored interventions to address the growing burden of non-communicable diseases and efforts around harnessing real world data. He also underscores the importance of investing in primary care and a primary health workforce against the backdrop of outbreaks such as coronavirus.
QUOTED. 24 February 2020. Daniel Taddeo.
Political tensions between Switzerland and the EU have led to concerns about the future status of the only Swiss medtech notified body, SQS. Here’s what SQS board member Daniel Taddeo said about the situation.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: